Samsung Biologics (KRX:207940) subsidiary Samsung Bioepis and Israel's Teva Pharmaceutical entered into a licensing, development, and commercialization agreement for EPYSQLI, or eculizumab-aagh, biosimilar to Soliris in the US.
Samsung Bioepis will handle the development, regulatory registration, manufacturing, and supply, while Teva Pharmaceutical will manage the product's commercialization.
EPYSQLI is a complement inhibitor used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, Samsung Bioepis said Friday.
Financial details of the deal were undisclosed.
Shares of Samsung Biologics rose more than 1% in recent trade on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.